Skip to main content

Olorofim FDA Approval Status

Last updated by Judith Stewart, BPharm on June 20, 2023.

FDA Approved: No
Generic name: olorofim
Company: F2G Inc.
Treatment for: Fungal Infections

Olorofim is a the first of the new orotomide class of antifungals in development for the treatment of difficult-to-treat invasive, rare fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare mold infections.

Development timeline for olorofim

Jun 20, 2023F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections
Dec 19, 2022F2G Announces FDA Filing Acceptance Of New Drug Application For Olorofim For The Treatment Of Invasive Fungal Infections

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.